GSK dou­bles down on vac­cines, HIV meds as CEO Em­ma Walm­s­ley touts 'land­mark' 2022

The step change that Em­ma Walm­s­ley promised at GSK is here, and the CEO has fi­nan­cial re­sults that sur­passed fore­casts to show for it.

GSK re­port­ed Q4 sales of near­ly £7.4 bil­lion, bring­ing full year 2022 sales to £29.3 bil­lion — which the British drug­mak­er said marks a 13% growth at con­stant ex­change rates. Record sales for Shin­grix, GSK’s shin­gles vac­cines, con­tributed a sig­nif­i­cant part of the growth.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER